Article Information
History
- May 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Bo Yu, MD, PhD1,
- Chenze Li, MD1,
- Peng Chen, MD, PhD1,
- Ning Zhou1,
- Luyun Wang, MD, PhD1,
- Jia Li, PhD2,
- Hualiang Jiang, PhD2,3 and
- Dao Wen Wang, MD, PhD1,*
- 1Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
- 2State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
- 3Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China
- ↵*Corresponding author Dao Wen Wang, MD, PhD, Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., Wuhan 430030, China, Tel./Fax 86-27-8366-2843, Email: dwwang{at}tjh.tjmu.edu.cn
Posted May 01, 2020.
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19
